Alyeska Investment Group’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-235,448
Closed -$2.34M 728
2021
Q3
$2.34M Hold
235,448
0.03% 482
2021
Q2
$2.34M Hold
235,448
0.03% 492
2021
Q1
$2.35M Hold
235,448
0.03% 445
2020
Q4
$2.54M Hold
235,448
0.04% 353
2020
Q3
$2.44M Buy
+235,448
New +$2.45M 0.04% 329

Other funds holding STLN

Alyeska Investment Group's STLN Position: Q4 2021 in Review

Alyeska Investment Group sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 235,448 shares — an estimated $2.34M sold.

Alyeska Investment Group first reported a position in STLN in Q3 2020 and held it in 5 quarters. The position peaked at $2.54M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Alyeska Investment Group reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 235,448 Starling Oncology shares in Q4 2021, an estimated $2.34M.
  • Alyeska Investment Group first reported a position in Starling Oncology in Q3 2020 and held it in 5 quarters.
  • Alyeska Investment Group's Starling Oncology position peaked at $2.54M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Alyeska Investment Group's 13F filing for Q4 2021, filed 14 Feb 2022.